688189 ST南新制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-4.752-15.917-30.937-1.631-5.725
总资产报酬率 ROA (%)-4.467-13.475-23.557-1.161-3.794
投入资产回报率 ROIC (%)-4.521-14.006-24.736-1.213-4.024

边际利润分析
销售毛利率 (%)14.99731.50352.50583.33785.788
营业利润率 (%)-64.217-93.413-149.416-3.248-10.287
息税前利润/营业总收入 (%)-73.786-93.470-150.223-2.457-9.585
净利润/营业总收入 (%)-72.583-105.515-153.075-3.470-13.743

收益指标分析
经营活动净收益/利润总额(%)75.24360.15020.442-144.933-53.804
价值变动净收益/利润总额(%)0.0000.0000.00070.7007.775
营业外收支净额/利润总额(%)12.2050.1260.152-0.9250.755

偿债能力分析
流动比率 (X)3.1304.2752.2902.9432.308
速动比率 (X)2.8873.8922.1102.8732.266
资产负债率 (%)16.91211.99128.15125.40733.676
带息债务/全部投入资本 (%)7.5171.16618.78420.44729.321
股东权益/带息债务 (%)1,225.1778,436.399430.395387.338239.254
股东权益/负债合计 (%)540.163807.263272.160298.084199.680
利息保障倍数 (X)114.945-1,548.718259.234-3.226-12.285

营运能力分析
应收账款周转天数 (天)81.449293.768512.185339.717339.337
存货周转天数 (天)132.671179.680137.81094.579160.282